Research ArticleNuclear Oncology
Overexpression of Glucose Transporter 1 and Increased FDG Uptake in Pancreatic Carcinoma
Sven N. Reske, Kurt G. Grillenberger, Gerhard Glatting, Matthias Port, Martin Hildebrandt, Frank Gansauge and Hans-Günther Beger
Journal of Nuclear Medicine September 1997, 38 (9) 1344-1348;
Sven N. Reske
Kurt G. Grillenberger
Gerhard Glatting
Matthias Port
Martin Hildebrandt
Frank Gansauge
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Overexpression of Glucose Transporter 1 and Increased FDG Uptake in Pancreatic Carcinoma
Sven N. Reske, Kurt G. Grillenberger, Gerhard Glatting, Matthias Port, Martin Hildebrandt, Frank Gansauge, Hans-Günther Beger
Journal of Nuclear Medicine Sep 1997, 38 (9) 1344-1348;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Opa1 and Drp1 reciprocally regulate cristae morphology, ETC function, and NAD+ regeneration in KRas-mutant lung adenocarcinoma
- Lysine methyltransferase 2D regulates pancreatic carcinogenesis through metabolic reprogramming
- Maltotriose Conjugation to a Chlorin Derivative Enhances the Antitumor Effects of Photodynamic Therapy in Peritoneal Dissemination of Pancreatic Cancer
- Diagnostic and Prognostic Value of ProEx C and GLUT1 in Melanocytic Lesions
- Antitumor Effects in Gastrointestinal Stromal Tumors Using Photodynamic Therapy with a Novel Glucose-Conjugated Chlorin
- Feasibility of 18F-Fluorodeoxyglucose Positron-emission Tomography for Preoperative Evaluation of Biliary Tract Cancer
- 123I-MIP-1072, a Small-Molecule Inhibitor of Prostate-Specific Membrane Antigen, Is Effective at Monitoring Tumor Response to Taxane Therapy
- CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in vivo and in vitro models
- Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma
- 18F-FDG PET Findings and GLUT-1 Expression in IPMNs of the Pancreas
- In Vivo Characterization of Proliferation for Discriminating Cancer from Pancreatic Pseudotumors
- Biologic Correlates of Intratumoral Heterogeneity in 18F-FDG Distribution with Regional Expression of Glucose Transporters and Hexokinase-II in Experimental Tumor
- Cellular Origin and Molecular Mechanisms of 18F-FDG Uptake: Is There a Contribution of the Endothelium?
- 3'-[18F]Fluoro-3'-Deoxythymidine ([18F]-FLT) as Positron Emission Tomography Tracer for Imaging Proliferation in a Murine B-Cell Lymphoma Model and in the Human Disease
- FDG Uptake and Glucose Transporter Subtype Expressions in Experimental Tumor and Inflammation Models
- Ki-67 Immunostaining in Pancreatic Cancer and Chronic Active Pancreatitis: Does In Vivo FDG Uptake Correlate with Proliferative Activity?
- In Vivo Evaluation of 5-[18F]Fluoro-2'-deoxyuridine as Tracer for Positron Emission Tomography in a Murine Pancreatic Cancer Model
- Glucose Metabolism of Breast Cancer Assessed by 18F-FDG PET: Histologic and Immunohistochemical Tissue Analysis
- Influence of Thyroid-Stimulating Hormone Levels on Uptake of FDG in Recurrent and Metastatic Differentiated Thyroid Carcinoma
- Phase I Trial of 6-Hour Infusion of Glufosfamide, a New Alkylating Agent With Potentially Enhanced Selectivity for Tumors That Overexpress Transmembrane Glucose Transporters: A Study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group